Brought to you by 
Basilea grants Pfizer European license to Cresemba; rights now include China and Asia Pacific
17 Jun 2022
Executive Summary
Basilea Pharmaceutica Ltd. licensed Pfizer Inc. exclusive rights to commercialize and distribute the antifungal Cresemba (isavuconazole) in European countries including Austria, France, Germany, Italy, and the UK, all territories where the drug is already being sold.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Basilea grants Pfizer European license to Cresemba; rights now include China and Asia Pacific
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice